Medication-related osteonecrosis of the jaw in cancer and osteoporosis patients: a retrospective seven-year single-center Norwegian cohort study of clinical profiles and documented soft tissue healing
DOI:
https://doi.org/10.2340/aos.v85.46983Keywords:
Osteonecrosis of the jaw, antiresorptive agents, neoplasms, osteoporosis, tooth extraction, retrospective studiesAbstract
Objective: To compare systemic profiles, oral findings, and documented soft tissue healing between cancer and osteoporosis patients with medication-related osteonecrosis of the jaw (MRONJ).
Material and methods: This retrospective single-center cohort included 105 cases treated in 2013–2019 (56 cancer; 49 osteoporosis). Healing at last follow-up was analyzed using adjusted logistic regression and Firth sensitivity analysis.
Results: Of 102 cases with known final status, 68 had documented healing. Osteoporosis cases were older, predominantly female, and had longer antiresorptive exposure than cancer cases (76.7 ± 11.1 vs. 70.0 ± 8.5 years; 102.5 ± 77.8 vs. 34.6 ± 28.5 months; both p < 0.001). Stage II predominated and Stage 0 was uncommon (3/105, 2.9%). Previous tooth extraction at the MRONJ lesion site was more frequent in osteoporosis (95.9% vs. 71.4%; p < 0.001). Surgical treatment was associated with higher healing odds (adjusted odds ratio [OR]: 11.12, 95% confidence interval [CI]: 4.12 to 33.35; p < 0.001), whereas cancer indication was associated with lower odds (adjusted OR: 0.23, 95% CI: 0.07 to 0.68; p = 0.011).
Conclusions: Systemic profiles differed; oral patterns were similar. Non-random treatment and missing healing dates limit interpretation. Previous tooth extraction was the most frequent antecedent event; its indication and timing were unverified.
Downloads
References
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56. DOI: https://doi.org/10.1016/j.joms.2014.04.031
Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(2):117–35. DOI: https://doi.org/10.1016/j.oooo.2018.09.008
Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369–76. DOI: https://doi.org/10.1016/j.joms.2006.11.003
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw – 2009 update. Aust Endod J. 2009;35(3):119–30. DOI: https://doi.org/10.1111/j.1747-4477.2009.00213.x
Coleman R. The use of bisphosphonates in cancer treatment. Ann N Y Acad Sci. 2011;1218:3–14. DOI: https://doi.org/10.1111/j.1749-6632.2010.05766.x
Bedogni A, Mauceri R, Fusco V, Bertoldo F, Bettini G, Di Fede O, et al. Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). Oral Dis. 2024;30(6):3679–709. DOI: https://doi.org/10.1111/odi.14887
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg. 2022;80(5):920–43. DOI: https://doi.org/10.1016/j.joms.2022.02.008
Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J, et al. Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study. Biol Pharm Bull. 2015;38(12):1850–5. DOI: https://doi.org/10.1248/bpb.b15-00385
Terpos E, Confavreux CB, Clézardin P. Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. Bonekey Rep. 2015;4:744. DOI: https://doi.org/10.1038/bonekey.2015.113
Lee K, Kim K, Kim JY, Kim JW, Kang YH, Kim YH, et al. Mechanisms underlying medication-related osteonecrosis of the jaw. Oral Dis. 2025;31(4):1073–83. DOI: https://doi.org/10.1111/odi.15198
Kuroshima S, Al-Omari FA, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: a literature review and update. Genesis. 2022;60(8–9):e23500. DOI: https://doi.org/10.1002/dvg.23500
Jiang A, Zhang Z, Qiu X, Guo Q. Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies. Arch Toxicol. 2024;98(3):689–708. DOI: https://doi.org/10.1007/s00204-023-03653-7
Zhao N, Li QX, Wang YF, Qiao Q, Huang HY, Guo CB, et al. Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts. BMC Oral Health. 2023;23(1):330. DOI: https://doi.org/10.1186/s12903-023-03034-7
Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177–87. DOI: https://doi.org/10.1016/j.ctrv.2018.06.007
Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341–7. DOI: https://doi.org/10.1093/annonc/mdr435
McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis. 2018;24(4):527–36. DOI: https://doi.org/10.1111/odi.12708
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23. DOI: https://doi.org/10.1002/jbmr.2405
Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol. 2019;37(25):2270–90. DOI: https://doi.org/10.1200/JCO.19.01186
Seluki R, Seluki M, Vaitkeviciene I, Jagelaviciene E. Comparison of the effectiveness of conservative and surgical treatment of medication-related osteonecrosis of the jaw: a systematic review. J Oral Maxillofac Res. 2023;14(4):e1. DOI: https://doi.org/10.5037/jomr.2023.14401
Choi NR, Lee JH, Park JY, Hwang DS. Surgical treatment of medication-related osteonecrosis of the jaw: a retrospective study. Int J Environ Res Public Health. 2020;17(23):8801. DOI: https://doi.org/10.3390/ijerph17238801
El-Rabbany M, Lam DK, Shah PS, Azarpazhooh A. Surgical management of medication-related osteonecrosis of the jaw is associated with improved disease resolution: a retrospective cohort study. J Oral Maxillofac Surg. 2019;77(9):1816–22. DOI: https://doi.org/10.1016/j.joms.2019.03.040
Fujimori M, Toriyabe Y, Sakakibara N, Nojima M, Makino S; Hokkaido Association of Hospital Dentistry Medication-Related Osteonecrosis of the Jaw Research Group. What Affects Healing rates in patients treated for medication-related osteonecrosis of the jaw? The role of operative therapy and other clinical factors. J Oral Maxillofac Surg. 2024;82(11):1441–55. DOI: https://doi.org/10.1016/j.joms.2024.06.176
Hadaya D, Soundia A, Freymiller E, Grogan T, Elashoff D, Tetradis S, et al. Nonsurgical management of medication-related osteonecrosis of the jaws using local wound care. J Oral Maxillofac Surg. 2018;76(11):2332–9. DOI: https://doi.org/10.1016/j.joms.2018.05.025
Ristow O, Rückschloß T, Müller M, Berger M, Kargus S, Pautke C, et al. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Craniomaxillofac Surg. 2019;47(3):491–9. DOI: https://doi.org/10.1016/j.jcms.2018.12.014
Rückschloß T, Smielowski M, Moratin J, Schnug G, Appel M, Muench P, et al. Comparing the influence of surgical and conservative therapy on quality of life in patients with early-stage medication-related osteonecrosis of the jaw – a prospective longitudinal study. Medicina (Kaunas). 2023;59(2):277. DOI: https://doi.org/10.3390/medicina59020277
Winter A, Schulz SM, Schmitter M, Brands RC, Straub A, Kübler A, et al. Oral-health-related quality of life in patients with medication-related osteonecrosis of the jaw: a prospective clinical study. Int J Environ Res Public Health. 2022;19(18):11709. DOI: https://doi.org/10.3390/ijerph191811709
Varoni EM, Lombardi N, Villa G, Pispero A, Sardella A, Lodi G. Conservative management of Medication-Related Osteonecrosis of the Jaws (MRONJ): a retrospective cohort study. Antibiotics (Basel). 2021;10(2):195. DOI: https://doi.org/10.3390/antibiotics10020195
Seki K, Kaneko T, Kamimoto A, Wada M, Takeuchi Y, Furuchi M, et al. Medication-related osteonecrosis of the jaw after tooth extraction in patients receiving pharmaceutical treatment for osteoporosis: a retrospective cohort study. J Dent Sci. 2022;17(4):1619–25. DOI: https://doi.org/10.1016/j.jds.2022.03.014
Corraini P, Heide-Jørgensen U, Schiødt M, Nørholt SE, Acquavella J, Sørensen HT, et al. Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark. Cancer Med. 2017;6(10):2271–7. DOI: https://doi.org/10.1002/cam4.1173
Hasegawa T, Hayashida S, Kondo E, Takeda Y, Miyamoto H, Kawaoka Y, et al. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study. Osteoporos Int. 2019;30(1):231–9. DOI: https://doi.org/10.1007/s00198-018-4746-8
Soutome S, Hayashida S, Funahara M, Sakamoto Y, Kojima Y, Yanamoto S, et al. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor? PLoS One. 2018;13(7):e0201343. DOI: https://doi.org/10.1371/journal.pone.0201343
Otto S, Tröltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg. 2015;43(6):847–54. DOI: https://doi.org/10.1016/j.jcms.2015.03.039
Bodem JP, Kargus S, Eckstein S, Saure D, Engel M, Hoffmann J, et al. Incidence of bisphosphonate-related osteonecrosis of the jaw in high-risk patients undergoing surgical tooth extraction. J Craniomaxillofac Surg. 2015;43(4):510–4. DOI: https://doi.org/10.1016/j.jcms.2015.02.018
Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg. 2010;68(4):797–804. DOI: https://doi.org/10.1016/j.joms.2009.10.026
Soutome S, Otsuru M, Hayashida S, Murata M, Yanamoto S, Sawada S, et al. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients. Sci Rep. 2021;11(1):17226. DOI: https://doi.org/10.1038/s41598-021-96480-8
Wang Y, Zhang Y, Li D, Zhang W, Wang S, Zheng X, et al. Potential role of the comprehensive tooth extraction procedure in preventing medication related osteonecrosis of the jaw (MRONJ): a prospective cohort study. Orphanet J Rare Dis. 2025;20(1):619. DOI: https://doi.org/10.1186/s13023-025-04138-9
Chang YS, Nanayakkara S, Yaacoub A, Cox SC. Prevention of medication-related osteonecrosis of the jaw: institutional insights from a retrospective study. Aust Dent J. 2025;70(1):70–7. DOI: https://doi.org/10.1111/adj.13050
Catania G, Monaco F, Limberti G, Alessio M, De Martino I, Barile C, et al. Osteonecrosis of the jaws (ONJ) after bisphosphonate treatment in patients with multiple myeloma: decreasing ONJ incidence after adoption of preventive measures. Dent J (Basel). 2016;4(4):45. DOI: https://doi.org/10.3390/dj4040045
Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, et al. The Dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int. 2018;2018:2684924. DOI: https://doi.org/10.1155/2018/2684924
Hadaya D, Soundia A, Gkouveris I, Dry SM, Aghaloo TL, Tetradis S. Development of medication-related osteonecrosis of the jaw after extraction of teeth with experimental periapical disease. J Oral Maxillofac Surg. 2019;77(1):71–86. DOI: https://doi.org/10.1016/j.joms.2018.08.010
Yazdi PM, Schiodt M. Dentoalveolar trauma and minor trauma as precipitating factors for medication-related osteonecrosis of the jaw (ONJ): a retrospective study of 149 consecutive patients from the Copenhagen ONJ Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119(4):416–22. DOI: https://doi.org/10.1016/j.oooo.2014.12.024
Schiodt M, Reibel J, Oturai P, Kofod T. Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(2):204–13. DOI: https://doi.org/10.1016/j.oooo.2013.10.010
Hallmer F, Bjørnland T, Andersson G, Becktor JP, Kristoffersen AK, Enersen M. Bacterial diversity in medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123(4):436–44. DOI: https://doi.org/10.1016/j.oooo.2016.11.011
Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. J Dent Res. 2015;94(4):534–9. DOI: https://doi.org/10.1177/0022034515572021
Hallmer F, Andersson G, Götrick B, Warfvinge G, Anderud J, Bjørnland T. Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;126(6):477–85. DOI: https://doi.org/10.1016/j.oooo.2018.08.015
Hallmer F, Bjarnadottir O, Götrick B, Malmström P, Andersson G. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;130(3):252–7. DOI: https://doi.org/10.1016/j.oooo.2020.04.808
Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122(1):181–8. DOI: https://doi.org/10.1007/s10549-010-0866-3
Yang M, Yu X. Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency. Support Care Cancer. 2020;28(6):2533–40. DOI: https://doi.org/10.1007/s00520-020-05355-7
Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 2010;141(11):1365–70. DOI: https://doi.org/10.14219/jada.archive.2010.0082
Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68(2):243–53. DOI: https://doi.org/10.1016/j.joms.2009.03.050
Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. J Clin Endocrinol Metab. 2014;99(8):2729–35. DOI: https://doi.org/10.1210/jc.2013-4119
Jung S, Kim J, Park JH, Kim KY, Kim HJ, Park W. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients. Sci Rep. 2022;12(1):8641. DOI: https://doi.org/10.1038/s41598-022-11615-9
Martins AS, Correia JA, Salvado F, Caldas C, Santos N, Capelo A, et al. Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws – a retrospective cohort study. J Craniomaxillofac Surg. 2017;45(10):1736–42. DOI: https://doi.org/10.1016/j.jcms.2017.07.014
Ruggiero SL, Kohn N. Disease stage and mode of therapy are important determinants of treatment outcomes for medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg. 2015;73(12 Suppl):S94–100. DOI: https://doi.org/10.1016/j.joms.2015.09.024
Lopes RN, Rabelo GD, Rocha AC, Carvalho PA, Alves FA. Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: six-year experience of a single institution. J Oral Maxillofac Surg. 2015;73(7):1288–95. DOI: https://doi.org/10.1016/j.joms.2015.01.008
Mücke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell DA, et al. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol. 2011;137(5):907–13. DOI: https://doi.org/10.1007/s00432-010-0953-1
Voss PJ, Joshi Oshero J, Kovalova-Müller A, Veigel Merino EA, Sauerbier S, Al-Jamali J, et al. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. J Craniomaxillofac Surg. 2012;40(8):719–25. DOI: https://doi.org/10.1016/j.jcms.2012.01.005
Choi WS, Lee JI, Yoon HJ, Min CK, Lee SH. Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma. Maxillofac Plast Reconstr Surg. 2017;39(1):1. DOI: https://doi.org/10.1186/s40902-016-0099-4
Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A, et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111(2):153–63. DOI: https://doi.org/10.1016/j.tripleo.2010.04.015
Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer. 2010;18(4):449–60. DOI: https://doi.org/10.1007/s00520-009-0688-1
Ferlito S, Puzzo S, Palermo F, Verzì P. Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases. Br J Oral Maxillofac Surg. 2012;50(5):425–9. DOI: https://doi.org/10.1016/j.bjoms.2011.08.004
Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E. Medication-related osteonecrosis of the jaw: surgical or non-surgical treatment? Oral Dis. 2018;24(1–2):238–42. DOI: https://doi.org/10.1111/odi.12764
Oteri G, Trifirò G, Peditto M, Lo Presti L, Marcianò I, Giorgianni F, et al. Treatment of medication-related osteonecrosis of the jaw and its impact on a patient’s quality of life: a single-center, 10-year experience from Southern Italy. Drug Saf. 2018;41(1):111–23. DOI: https://doi.org/10.1007/s40264-017-0582-6
Ramaglia L, Guida A, Iorio-Siciliano V, Cuozzo A, Blasi A, Sculean A. Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Investig. 2018;22(2):597–615. DOI: https://doi.org/10.1007/s00784-017-2325-6
Rollason V, Laverrière A, MacDonald LC, Walsh T, Tramèr MR, Vogt-Ferrier NB. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane Database Syst Rev. 2016;(2):CD008455. DOI: https://doi.org/10.1002/14651858.CD008455.pub2
Goker F, Grecchi E, Grecchi F, Francetti L, Del Fabbro M. Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review. Eur Rev Med Pharmacol Sci. 2021;25(6):2662–73.
Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer. 2016;24(1):447–55. DOI: https://doi.org/10.1007/s00520-015-2904-5
Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370–81. DOI: https://doi.org/10.1016/S1470-2045(18)30072-X
Schiodt M, Otto S, Fedele S, Bedogni A, Nicolatou-Galitis O, Guggenberger R, et al. Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges. Oral Dis. 2019;25(7):1815–21. DOI: https://doi.org/10.1111/odi.13160
Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg. 2015;53(1):13–17. DOI: https://doi.org/10.1016/j.bjoms.2014.09.001
Watters AL, Hansen HJ, Williams T, Chou JF, Riedel E, Halpern J, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(2):192–200. DOI: https://doi.org/10.1016/j.oooo.2012.05.017
Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Myers J, Li Y, et al. Medication-related osteonecrosis of the jaw in patients treated concurrently with antiresorptive and antiangiogenic agents: systematic review and meta-analysis. J Immunother Precis Oncol. 2021;4(4):196–207. DOI: https://doi.org/10.36401/JIPO-21-14
Sacco R, Woolley J, Patel G, Calasans-Maia MD, Yates J. Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy? Br J Oral Maxillofac Surg. 2022;60(2):e216–30. DOI: https://doi.org/10.1016/j.bjoms.2021.03.006
Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent. 2021;7(1):47. DOI: https://doi.org/10.1186/s40729-021-00323-0
Additional Files
Published
Issue
Section
License
Copyright (c) 2026 Safiyye Süslü, Håvard J. Haugen, Tormod B. Krüger, Janne Elin Reseland, Bente Brokstad Herlofson
This work is licensed under a Creative Commons Attribution 4.0 International License.
Acta Odontologica Scandinavica publishes high quality original research papers as well as critical reviews relevant on diseases of the oral cavity, their treatment, epidemiology and associated biomaterials and their development.
